AzTrials
AzTrials

Pancreas CancerPRECEDENCT04970056

Pancreatic Cancer Early Detection Consortium

An observational study of Pancreas Cancer and Pancreas Cyst, run by Arbor Research Collaborative for Health at 60 sites in 11 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely… Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
How many people
20,000 participants
Where
60 sitesin 11 countries
Study dates
18 Sep 2020to 31 Dec 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study will accrue subjects who present for risk assessment at one of the participating sites based on history of: * one or more family members with PDAC * a pathogenic or likely pathogenic germline variant in a gene linked to PDAC risk * personal history of PDAC with PGV in genes of research interest and/or part of a Familial Pancreatic Cancer kindred

Who may be able to join

  • Individuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:
  • Cohort 1
  • Individuals without history of PDAC meeting any of the following criteria:
  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
  • 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
Show all 29Show fewer
  • Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
  • Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
  • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
  • Cohort 2
  • Individuals without history of PDAC meeting any of the following criteria:
  • ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
  • 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
  • 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
  • Cohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
  • Cohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
  • Cohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
  • Cohort 6a
  • Individuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:
  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • Cohort 6b
  • Individuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:
  • Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  • Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  • Diagnosed ≤ age 45
  • Cohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.
  • Cohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.
  • Cyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)

Who cannot join

  • Individuals not meeting the criteria above.

Trial locations and contacts

60 sites in 11 countries. Contact the study team or a site near you to ask about taking part.

Naveen Fawas, BS contact

7346654108

naveen.fawaz@arborresearch.org

John Graff, PhD contact

7346654108

john.graff@arborresearch.org

60 sites in 11 countries

United States45 sites, 42 recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Sarah Volk, stomanic@med.umich.edu

    Erika Koeppe, eskoeppe@med.umich.edu

    Recruiting

  • Emory University Hospital

    Atlanta, Georgia, 30322

    Halley Fowler, halley.fowler@emory.edu

    Saurabh Chawla, MD, AGAF, FACG, FASGE

    Recruiting

  • Illinois CancerCare

    Bloomington, Illinois, 61704

    Carrie Geoffroy, cgeoffroy@illinoiscancercare.com

    Kimberly Ku, MD

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

    Danielle Lynch, dlynch22@mgh.harvard.edu

    Daniel Chung

    Recruiting

  • Providence Health and Services

    Burbank, California, 91505

    Taridu Ekanayake, emtaridu.ekanayake@providence.org

    Ora Gordon, MD, MS. FACMG

    Recruiting

  • University of Virginia

    Charlottesville, Virginia, 22903

    Evelyn Garcia, ev4pd@uvahealth.org

    Todd Bauer, MD

    Recruiting

  • University of Chicago Medicine

    Chicago, Illinois, 60637

    Nia Howard, nia.howard@bsd.uchicago.edu

    Sonia Kupfer, MD

    Recruiting

  • The Ohio State University

    Columbus, Ohio, 43210

    Ashley Tyson, 614-814-6487, Ashley.Tyson@osumc.edu

    Philip Hart, MD

    Recruiting

  • The University of Texas Southwestern Medical Center

    Dallas, Texas, 75390

    Terminated

  • City of Hope

    Duarte, California, 91010

    Diamond Ward, diward@coh.org

    James Lin

    Recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201

    Aram Rojas, arojas@northshore.org

    Melissa Hogg, MD

    Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031

    Salman Baig, Salman.Baig@inova.org

    Raymond Wadlow, MD

    Recruiting

  • Hackensack Meridian Health

    Hackensack, New Jersey, 07601

    Christianna Torres, christianna.torres@hmhn.org

    Rosario Ligresti, MD

    Recruiting

  • MD Anderson Center

    Houston, Texas, 77030

    Withdrawn

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224

    Christian Glover, glover.christian@mayo.edu

    Yan Bi

    Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160

    Jodi Claybaugh, jclaybaugh@kumc.edu

    Ajay Bansal, MD

    Recruiting

  • University of Tennessee Graduate School of Medicine

    Knoxville, Tennessee, 37930

    Tiffany Johnson, thjohnson@utmck.edu

    James McLoughlin, MD

    Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093

    Emma Vail, e2brooks@health.ucsd.edu

    Diane Simeone, MD

    Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048

    Jenny Frisendahl, jenny.frisendahl@cshs.org

    Srinivas Gaddam

    Recruiting

  • UCLA Health

    Los Angeles, California, 90095

    Sophia Quiroz, SStokes@mednet.ucla.edu

    Timothy Donahue, MD

    Recruiting

  • University of Miami

    Miami, Florida, 33136

    Casper Ruiz Ruiz, cxr1353@med.miami.edu

    Dan Sussman

    Recruiting

  • Yale University

    New Haven, Connecticut, 06510

    Scott Merenda, scott.merenda@yale.edu

    James Farrell

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10022

    Jeffin Naduparambil, naduparj@mskcc.org

    Vineet Rolston, MD

    Not yet recruiting

  • Icahn School of Medicine At Mount Sinai

    New York, New York, 10029

    Joyce Serebrenik, joyce.serebrenik@mountsinai.org

    Storey Harbison, storey.harbison@mssm.edu

    Recruiting

  • Columbia University Irving Medical Center

    New York, New York, 10032

    Katharine Godfrey, kb3217@cumc.columbia.edu

    Fay Kastrinos

    Recruiting

  • Hoag

    Newport Beach, California, 92663

    Alexandria Adams, alexandria.adams@hoag.org

    Zulma Loera, zulma.loera@hoag.org

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Suzanne Wessling, suzanne.wessling@unmc.edu

    Kelsey Klute

    Recruiting

  • UC Irvine Health

    Orange, California, 92868

    Blake Johnson, blakej@hs.uci.edu

    Jennifer Valerin, MD, PhD

    Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

    Danny Clay, Daniel.Clay@Pennmedicine.upenn.edu

    Bryson Katona

    Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111

    Eberechukwu Muoneke, eberechukwu.muoneke@fccc.edu

    David Weinberg, MD, MSc

    Recruiting

  • Mayo Clinic Arizona

    Phoenix, Arizona, 85054

    Michele Richardson, richardson.michele@mayo.edu

    Michelle Anderson

    Not yet recruiting

  • University of Pittsburgh Medical Center (Upmc)

    Pittsburgh, Pennsylvania, 15232

    Beth Dudley, dudleyre@upmc.edu

    Randy Brand

    Recruiting

  • Oregon Health & Science University

    Portland, Oregon, 97239

    Dove Keith, keithd@ohsu.edu

    Aaron Grossberg

    Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298

    Faith McFadden, mcfaddenfr@vcu.edu

    Jose Trevino, MD

    Recruiting

  • University of Rochester Medical Center

    Rochester, New York, 14642

    Chelsea DiBella, chelsea_dibella@urmc.rochester.edu

    Darren Carpizo

    Recruiting

  • Beaumont/Corewell Health

    Royal Oak, Michigan, 48073

    Tara Rangarajan, tara.rangarajan@corewellhealth.org

    Dana Zakalik, MD

    Recruiting

  • UC Davis

    Sacramento, California, 95817

    Tanpreet Dodd, tkdodd@health.ucdavis.edu

    Edward Kim, MD, PhD

    Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah, 84112

    Jo Lyman, jo.anson@hci.utah.edu

    Whitney Espinel, MMSc, GC

    Recruiting

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94143

    Kurt Giles, PancreasCRC@ucsf.edu

    Margaret Tempero, MD

    Recruiting

  • Honor Health Research Institute

    Scottsdale, Arizona, 85258

    Jeanette Dupree, jdupree@honorhealth.com

    Erkut Borazanci, MD

    Recruiting

  • University of Washington

    Seattle, Washington, 98195

    Lisa Ann Lai, lail@uw.edu

    Teri Brentnall

    Recruiting

  • Intermountain Health

    St. George, Utah, 84790

    Withdrawn

  • Moffitt Cancer Center

    Tampa, Florida, 33612

    Toni Basinski, 813.745.6360, Toni.Basinski@Moffitt.Org

    Jenny Permuth

    Recruiting

  • White Plains Hospital

    White Plains, New York, 10601

    Griselda Cruz, grcruz@wphospital.org

    Joshua Raff, MD

    Recruiting

  • Umass Memorial Medical Center

    Worcester, Massachusetts, 01655

    Paige Malone, paige.malone@umassmed.edu

    James Lindberg, MD

    Recruiting

Other trials in United States

Canada3 sites, 3 recruiting

  • McGill University Health Centre

    Montreal, Quebec

    Adeline Cuggia, pancreas.surveillance@muhc.mcgill.ca

    George Zogopoulos

    Recruiting

  • University Health Network

    Toronto, Ontario

    Spring Holter, spring.holter@uhn.ca

    Robert Grant

    Recruiting

  • British Columbia Cancer Agency

    Vancouver, British Columbia

    Eugene Cheung, eugene.cheung1@bccancer.bc.ca

    Intan Schrader

    Recruiting

Other trials in Canada

Spain3 sites, 3 recruiting

  • Hospital Clínic de Barcelona

    Barcelona

    Eva Vaquero, evaquero@clinic.cat

    Eva C Vaquero, MD, PhD

    Recruiting

  • Hospital Universitari Arnau De Vilanova

    Lleida, 25198

    Xavier Molero, xmolero@gss.cat

    Xavier Molero, MD, PhD

    Recruiting

  • Ramón y Cajal University Hospital

    Madrid

    Julie Earl, julie.earl@live.co.uk

    Julie Earl

    Recruiting

Other trials in Spain

Taiwan2 sites, 2 recruiting

  • National Cheng Kung University Hospital (NCKUH)

    Tainan, Taiwan T.o.c., 704

    Yung-Yeh Su, yysu@nhri.edu.tw

    Yan-Shen Shan

    Recruiting

  • National Taiwan University Hospital

    Taipei

    Wei-Chih David Liao, david.ntuh@gmail.com

    Wei-Chih David Liao, MD, PhD

    Recruiting

Other trials in Taiwan

Australia1 site, 1 recruiting

  • Epworth HealthCare

    Richmond, Victoria, 3121

    Ashleigh Poh, ashleigh.poh@epworth.org.au

    Andrew Metz, MBBS, FRACP

    Recruiting

Other trials in Australia

Hungary1 site, 1 recruiting

  • Semmelweis University, Institute of Pancreatic Diseases

    Budapest

    Zoltán Hajnády, hajnady.zoltan@semmelweis.hu

    Péter Hegyi, MD, PhD, DSc

    Recruiting

Other trials in Hungary

Iceland1 site, 1 recruiting

  • Landspitali University Hospital

    Reykjavik

    Jóhanna Stefansdottir, johanste@landspitali.is

    Sigurdís Haraldsdóttir, MD

    Recruiting

Other trials in Iceland

Israel1 site, 1 recruiting

  • Sheba Medical Center

    Ramat Gan

    Maria Raitses, Maria.RaitsesGurevich@sheba.health.gov.il

    Talia Golan

    Recruiting

Other trials in Israel

Italy1 site, 1 recruiting

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona

    Salvatore Paiella, salvatore.paiella@univr.it

    Erica Secchettin, erica.secchettin@univr.it

    Recruiting

Other trials in Italy

Singapore1 site, 1 recruiting

  • National Cancer Centre Singapore

    Singapore, 168583

    Caitlin Nicole, caitlin.nicole.s.v@nccs.com.sg

    Meggie Huang Mochao, meggie.huang.m.c@nccs.com.sg

    Recruiting

Other trials in Singapore

United Kingdom1 site, 1 recruiting

  • University of Liverpool

    Liverpool

    Annabelle Boughey, europac@liverpool.ac.uk

    Bill Greenhalf

    Recruiting

Other trials in United Kingdom

About this study

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Read the detailed description

The main objective of the PRECEDE Consortium is to build a shared resource to drive research in critical areas necessary for early detection and prevention of PDAC.

The PRECEDE Consortium is an observational prospective cohort study, with single or serial biosample collection (every 6-12 months) in defined high-risk groups.

A standardized procedure for collection and processing of human blood for the PRECEDE Consortium will be applied to all blood samples collected as part of the study. Barcoded samples will be stored at the clinical centers, using the specific labels for the PRECEDE study and corresponding data will be entered into the study database.

Clinical data and outcomes will be obtained from institutional databases or clinical records to correlate patient information with laboratory results from biospecimens obtained for research. Patients will be followed by their attending physician and receive the standard follow-up care after the procedure in which biospecimen was obtained. It is the intent that biospecimens will be made available to all consortium investigators.

Medical subject headings
Pancreatic Neoplasms, Pancreatic Cyst, Genetic Predisposition to Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04970056
Study groupRoleWhat they receive
Cohort 1Individuals without history of PDAC meeting any of the following criteria: 1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis. 2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family 3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family 4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+ 5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+ 6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
Cohort 2Individuals without history of PDAC meeting any of the following criteria: 1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+ 2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family 3. 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
Cohort 3Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)
Cohort 4Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.
Cohort 5Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.
Cyst CohortIndividuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)
Cohort 6aIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria: 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
Cohort 6bIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria: 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11 3. Diagnosed ≤ age 45
Cohort 6cIndividuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.
Cohort 6dIndividuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of PDAC

    Diagnosis of PDAC

    Measured: Through study completion, an average of 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jul 2021
  2. Study start18 Sep 2020
  3. Primary completion31 Dec 2030 (estimated)
  4. Study completion31 Dec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
20,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04970056
Sponsor's protocol ID
PRECEDE
Acronym
PRECEDE
Status last verified
Jul 2026
First submitted
21 Apr 2021
Last updated
22 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Zogopoulos G, Haimi I, Sanoba SA, Everett JN, Wang Y, Katona BW, Farrell JJ, Grossberg AJ, Paiella S, Klute KA, Bi Y, Wallace MB, Kwon RS, Stoffel EM, Wadlow RC, Sussman DA, Merchant NB, Permuth JB, Golan T, Raitses-Gurevich M, Lowy AM, Liau J, Jeter JM, Lindberg JM, Chung DC, Earl J, Brentnall TA, Schrader KA, Kaul V, Huang C, Chandarana H, Smerdon C, Graff JJ, Kastrinos F, Kupfer SS, Lucas AL, Sears RC, Brand RE, Parmigiani G, Simeone DM; PRECEDE Consortium. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. J Natl Compr Canc Netw. 2024 Apr;22(3):158-166. doi: 10.6004/jnccn.2023.7097.

    PubMed 38626807

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreas Cancer and Pancreas Cyst, run by Arbor Research Collaborative for Health at 60 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 60 sites in United States, Canada, Spain, Taiwan, Australia and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Naveen Fawas, BS (7346654108, naveen.fawaz@arborresearch.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of PDAC (time frame: Through study completion, an average of 6 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04970056, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Pancreatic Cancer Early Detection Consortium | AzTrials